News Breaks |
|
|
| February 21, 2013 |
| 09:04 EDT |  | ALXA | Alexza Pharmaceuticals receives marketing authorization for Adasuve in EU
Alexza Pharmaceuticals announced that the European Commission has granted marketing authorization for Adasuve. In the European Union, Adasuve, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects. |
|
|
News For ALXA From The Last 14 Days Check below for free stories on ALXA the last two weeks. |
|
|
| May 14, 2013 |
| 16:13 EDT |  | ALXA | Alexza Pharmaceuticals reports Q1 EPS ($1.31), consensus (45c)
 Subscribe for More Information |
|
| May 8, 2013 |
| 12:39 EDT |  | ALXA | Options with increasing implied volatility: ALXA FIO EBIX VMED HNZ
Subscribe for More Information |
|
| 12:00 EDT |  | ALXA | Alexza Pharmaceuticals rises 23.7%
Alexza Pharmaceuticals is up 23.7%, or $1.03, to $5.37 |
|
| 10:26 EDT |  | ALXA | Alexza deal with Teva could be worth $12 per share or more, says Roth Capital
Subscribe for More Information |
|
| 10:01 EDT | | ALXA | Alexza Pharmaceuticals rises 32.7%
Subscribe for More Information |
|
| 09:06 EDT |  | ALXA | Alexza Pharmaceuticals to host conference call
Subscribe for More Information |
|
| 08:33 EDT | | ALXA | Teva, Alexza announce Teva's license to market Adasuve in the U.S.
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. |
|
| 08:25 EDT | | ALXA | Alexza Pharmaceuticals trading halted, pending news
Subscribe for More Information |
|
|
|
|
|
